What risks should providers bear in mind when considering prescribing newer hypoglycemic agents?
When deciding whether to prescribe newer hypoglycemic agents, providers should bear in mind the potential for safety concerns that could emerge when these drugs are adopted into wider use, such as the FDA imposed restrictions on use of rosiglitazone due to data that suggests an increased risk of cardiovascular complications.